ADMA Biologics faces an August 10 deadline for lead plaintiff applications in a securities fraud class action
Executive summary: Kahn Swick & Foti issued a press notice informing ADMA Biologics investors that the deadline to apply for lead plaintiff status in a securities fraud class action is August 10, 2026. The deadline determines who can steer the litigation, potentially influencing settlement terms and legal costs for ADMA.
Who is involved: ADMA Biologics (Nasdaq: ADMA), investors holding shares during the alleged class period, and law firm Kahn Swick & Foti (partner Charles C. Foti Jr.).
Likely next: Investors will submit lead plaintiff applications by the deadline; if selected, the case will proceed to discovery and possible settlement or trial.
Kahn Swick & Foti notified ADMA investors of the upcoming deadline to seek lead plaintiff status in a lawsuit alleging misrepresentations about the company's financial condition and revenue. The notice follows a series of similar alerts issued by the same law firm for other biotech and tech firms, indicating a coordinated outreach effort. While the filing does not imply guilt, it highlights ongoing legal exposure that could affect ADMA's share price and corporate resources. Investors must decide whether to pursue lead plaintiff roles before the August 10 cutoff.
Timeline
- — ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline (PR Newswire)
Analysis — what this means
Likely next events
- August 10, 2026: Lead plaintiff application deadline for ADMA Biologics class action
- September 22, 2026: Application deadline for Wix.com Ltd. class action (same law firm)
- August 10, 2026: Parallel deadlines for Erasca, Via Transportation, and Zillow Group class actions
Sectors affected
- Biologics
- Biotechnology
Regulatory implications
- Potential SEC scrutiny over alleged financial misrepresentations
- Possible enforcement under Securities Exchange Act §§10(b) and 20(a) if violations proven
- Increased oversight of class action filing deadlines by private plaintiffs' attorneys
Historical parallels
- Biogen Inc. securities class action settlement in 2021 over alleged misleading statements about Alzheimer's drug
- Gilead Sciences 2020 class action concerning HCV drug pricing disclosures
Key entities
Sources
Related cases
- Pomerantz Law Firm files class action against ADMA Biologics, with investor deadline of August 10, 2026, amid repeated securities fraud alerts
- ADMA Biologics faces renewed securities litigation pressure as DJS Law Group reactivates investor outreach for August 2026 class action
- ADMA Biologics faces a looming August 10 deadline for investors to assume lead plaintiff role in a securities fraud class action, highlighting ongoing litigation risk for the biotech firm
- Rosen Law Firm reminds ADMA Biologics investors of the August 10 deadline to serve as lead plaintiff in a securities fraud class action
- ADMA Biologics faces a securities class action alleging violations of federal anti‑fraud statutes, raising legal and investor confidence risks
- ADMA Biologics shareholders invited to lead securities fraud class action over alleged financial misrepresentations